References
- Hatlebakk JG, Berstad A. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clin Pharmacokin 1996;31:386–406.
- Ekström P, Carling L, Unge P, Anker-Hansen O, Sjöstedt S, Sellström H. Lansoprazole vs omeprazole in active duodenal ulcer. Scand J Gastroenterol 1995;30:210–5.
- Castell DO, Richter JE, Robinson M, Sontag SJ, Haber MM, The Lansoprazole Group. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. Am J Gastroenterol 1996;91:9:1749–57.
- Mee AS, Rowley JL, the Lansoprazole clinical research group. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther 1996; 10:757–63.
- Hatlebakk JG, Berstad A, Carling L, Svedberg L-E, Unge P, Ekström P, et al. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial. Scand J Gastroenterol 1993;28:224–8.
- Tolman KG, Sanders SW, Buchi KN, Karol MD, Jennings DE, Ringham GL. The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol 1997;24:2:65–70.
- Dammann HG, Fuchs W, Richter G, Burkhardt F, Wolf N, Walter TA. Lansoprazole vs omeprazole: influence on meal-stimulated gastric acid secretion. Aliment Pharmacol Ther 1997;11:359–64.
- Joelsson B, Johnsson F. Heartburn—the acid test. Gut 1989; 30:1523–5.
- Bell NJV, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992;33: 118–24.
- Smith JL, Opekun AR, Larkai E, Graham DY. Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology 1989;96:683–9.
- Siddiqui MA, Johnston BT, Leite LP, Katzka DA, Castell DO. Sensitization of esophageal mucosa by prior acid infusion: effect of decreasing intervals between infusions. Am J Gastroenterol 1996;91:1745–8.
- Lind T, Havelund T, Carlsson R, Anker-Hansen O, Glise H, Hernqvist H, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974–9.
- Gerloff J, Mignot A, Barth H, Heintze K. Pharmacokinetics and absolute bioavailability of lansoprazole. Eur J Clin Pharmacol 1996;50:293–7.
- Blum RA. Lansoprazole and omeprazole in the treatment of acid peptic disorders. Am J Health Syst Pharm 1996;53:1401–15.
- Andersson T, Cederberg C, Heggelund A, Lundborg P. The pharmacokinetics of single and repeated once-daily doses of 10, 20 and 40 mg omeprazole as enteric-coated granules. Drug Invest 1991;3:45–52.
- Naesdal J, Bodemar G, Walan A. Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease. Scand J Gastroenterol 1984;19: 916–22.
- Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole—a gastric proton pump inhibitor—on pentagastrin stimulated acid secretion in man. Gut 1983;24:270–6.
- Florent C, Forestier S. Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30 mg and pantoprazole 40 mg. Eur J Gastroent Hepatol 1997;9:195–200.
- Sanders SW, Tolman KG, Greski PA, Jennings DE, Hoyos PA, Page JG. The effects of lansoprazole, a new H+, K+-ATPase inhibitor, on gastric pH and serum gastrin. Aliment Pharmacol Ther 1992;6:359–72.
- Garner A, Fadlallah H. Pantoprazole: a new and more specific proton pump inhibitor. Exp Opin Invest Drugs 1997;6:885–93.